[144] VERACYTE, INC. SEC Filing

Rhea-AI Filing Summary

Veracyte (VCYT) reports a proposed sale of 2,160 common shares, representing restricted stock units acquired on 03/02/2025, with an aggregate market value of $74,152.80. The shares are to be sold through Morgan Stanley Smith Barney LLC on or about 10/01/2025 on the NASDAQ. The issuer's outstanding shares are listed as 78,671,588, so the proposed sale equals approximately 0.0027% of outstanding shares. The filing also discloses prior 10b5-1 sales by the same account of 2,283 shares on 09/19/2025 for gross proceeds of $76,919.50. The securities were acquired as Restricted Stock Units from the issuer and no cash payment was required at acquisition.

Positive

• Transparency: The filing discloses broker, acquisition method (RSUs), number of shares, and aggregate market value.
• Orderly execution: Sale is to be handled by a named broker (Morgan Stanley Smith Barney LLC), suggesting professional execution.
• Prior planned sales: Recent 10b5-1 sales (2,283 shares) were disclosed, indicating use of prearranged trading plans.

Negative

• Insider sale: An insider proposes to sell shares, which some investors may view negatively despite small size.
• No forward-looking context: The filing provides no information about the seller's reasons or future intentions beyond the sale notice.

Insights

Securities Analyst

TL;DR: Insider plans a modest sale of RSUs worth ~$74K, representing a negligible fraction of outstanding shares; prior 10b5-1 sales occurred.

This Form 144 notifies the market that 2,160 shares arising from Restricted Stock Units granted by the issuer will be offered for sale through Morgan Stanley Smith Barney. The aggregate value of the proposed sale is $74,152.80, and the filing quantifies prior dispositions: 2,283 shares sold under a 10b5-1 plan for $76,919.50. Given the issuer's reported outstanding share count of 78,671,588, the proposed sale is immaterial in size (~0.0027%). The disclosure is routine: it provides required transparency about insider liquidity while identifying the broker and sale mechanics.

Corporate Governance Expert

TL;DR: The filing documents an orderly sale of RSUs via a broker with prior 10b5-1 activity; no new governance concerns are disclosed.

The notice states the securities were acquired as RSUs from the issuer on 03/02/2025 and that the seller represents no undisclosed material nonpublic information. The sale will be executed through a named broker and lists an approximate trade date. A recent sale under a 10b5-1 plan is also disclosed, indicating the filer has used prearranged sales mechanisms. The filing contains required attestations but does not disclose any material corporate governance events or changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2160	74152.80	78671588	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/02/2025	Restricted Stock Units	Issuer			2160	03/02/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ANN MCGUIRE 6000 Shoreline Court, Suite 300 South San Francisco CA 94080	Common	09/19/2025	2283	76919.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Veracyte's (VCYT) Form 144 disclose about the proposed sale?

The Form 144 discloses a proposed sale of 2,160 common shares (RSUs) valued at $74,152.80, to be sold through Morgan Stanley Smith Barney LLC on or about 10/01/2025 on the NASDAQ.

How and when were the securities to be sold acquired?

The securities were acquired as Restricted Stock Units from the issuer on 03/02/2025, with no cash payment required at acquisition.

Has the filer sold any Veracyte shares recently?

Yes. The document reports prior 10b5-1 sales of 2,283 shares on 09/19/2025 for gross proceeds of $76,919.50.

What portion of Veracyte's outstanding shares does this sale represent?

Using the reported outstanding shares of 78,671,588, the proposed sale of 2,160 shares equals approximately 0.0027% of outstanding shares.

Who will execute the sale and on which exchange?

The sale is to be executed by Morgan Stanley Smith Barney LLC and the securities are listed to trade on the NASDAQ.